95在线高清免费观看电视剧-97影院在线观看免费高清电视剧狂飙-97在线观看免费高清电视剧大全八戒-999影院在线观看免费最新电视剧

彌漫性大B細胞淋巴瘤(DLBCL)是一種最常見的非霍奇金淋巴瘤，診斷病例在美國約占淋巴瘤的30%。它是一種特異質性疾病。由于臨床多樣性和復雜性,又有新的突變在某些難治性患者身上被發現。阿斯利康需要創建一種彌漫性巨大B細胞淋巴瘤的合適的臨床模型。 具體鏈接在：https://www.innocentive.com/ar/challenge/9933016 AstraZeneca Challenge: Developing Clinically-Relevant Models for Diffuse Large B Cell Lymphoma (DLCBL) TAGS: AstraZeneca, Physical Sciences, Life Sciences, Nature, Requests for Partners and Suppliers, Chemistry, RTP AWARD: See details | DEADLINE: 6/02/15 | ACTIVE SOLVERS: 9 | POSTED: 3/04/15 Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and accounts for up to 30% of newly diagnosed cases in the United States. It is a heterogeneous disease which in part appears to be driven by chronic activation of key survival pathways. A limited number of DLBCL cell lines are available, however there are gaps, and specific patient subtypes are not represented. To add to the complexity of clinical diversity, new mutations are being identified in certain treatment-resistant patients. AstraZeneca is interested in innovative proposals to create suitable preclinical models of DLBCL. This is a Reduction-to-Practice Challenge that requires a written proposal and experimental proof-of-concept data (and/or sample delivery). The Challenge has a special award structure. Whether creating a model for DLBCL or a model of acquired resistance to ibrutinib, up to $10,000 will be designated for solutions that highlight novel technologies to generate in vitro cell lines, whereas up to $25,000 will be awarded for submissions that successfully utilize patient-derived tissues.

靜脈注射的優點就是快速靜脈注射藥物的分布在整個身體。通常,這些藥物總是快速代謝，快速排出，導致短期的臨床療效。大家可以從微丸持續釋放顯效得皮啟發。具體看鏈接：https://www.innocentive.com/ar/challenge/9933723 Intravenous delivery allows for the rapid distribution of injected drugs from the veins throughout the entire body. Oftentimes, these drugs are quickly metabolized and excreted resulting in short durations of clinical efficacy. Certain therapies may benefit from a bolus followed by sustained release. The Seeker wishes to identify a technology to sustain the delivery of a human high dose intravenous drug from a single injection administered over a period of 15 to 30 minutes. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933723 Challenge Overview An intravenous sustained drug delivery technology is desired for a high dose drug that needs to be delivered over 8 to 10 hours. This intravenous sustained release delivery technology would allow a bolus of drug (approximately 40 to 60%) to be delivered quickly upon intravenous administration followed by the remaining dose (60 to 40%) delivered in a near zero order fashion from this intravenous administration over an 8 to 10 hour interval. This drug delivery technology needs to use materials that are already recognized as safe or can be easily qualified for parenteral administration in humans. This drug delivery technology should present no encumbrance to nurses administering the drug in a hospital setting. This technology should be amenable to delivering about 2 grams of a drug with an aqueous solubility of approximately 0.75 grams in 50 mL at 25°C and approximately 1 gram in 50 mL at 37°C during the 8 to 10 hour interval. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on March 21, 2015. Late submissions will not be considered. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker.

排行世界的第五大的制藥公司尋找合作伙伴，要求提供多種大環結構藥物與合成技術，尋找有關大環領域的新藥發現。希望此公司提供化學詳細的3 d模型。具體請鏈接：https://www.innocentive.com/ar/challenge/9933642 The Seeker, a top-five big pharma company, is looking for collaboration partners with expertise in the area of macrocycle drug discovery. Specifically, three key areas are of interest: Chemistry partners with access to diverse macrocyclic structures & synthetic expertise In-silico chemistry partners with access to high-throughput 3-D models suitable for macrocycles In-vitro ADME experts with access to membrane systems, beyond PAMPA and Caco-2 This is an electronic Request-for-Partners (eRFP) Challenge. The Solver will write a preliminary proposal (about 2–4 pages including contact information) to be evaluated by the Seeker with a goal of establishing a collaborative partnership. Upon completion of the evaluation, the Seeker may contact selected Solvers directly to work out terms for a collaboration contract. The monetary value of the contract will vary depending on the amount of work to be delivered and the time frame agreed upon.

抑制細胞外神經信號的作用可以通過抑制受體或去除配位體來產生。我們需要一個實例或證據來證明抑制受體和損耗配體是怎么阻斷信號的，比如可以變構小分子或大分子或競爭性抑制。具體看下面鏈接： https://www.innocentive.com/ar/challenge/9933720 AWARD: $20,000 USD | DEADLINE: 2/25/15 | ACTIVE SOLVERS: 19 | POSTED: 1/26/15 Inhibition of extracellular signaling can occur through an inhibition of a receptor or removal of a ligand. What evidence is there that one method of inhibition is more efficient or efficacious than the other at blocking signaling? The Seeker is specifically looking for well-supported examples of receptor/ligand inhibition where both methods of inhibition exist. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933720 Challenge Overview Inhibition of extracellular neuronal signaling can occur through the inhibition of a receptor or removal of a ligand. What evidence is there (or lack of) that one method of inhibition (inhibition of the receptor versus depletion of the ligand) is more efficient or efficacious than the other at blocking signaling? Inhibition can be allosteric or competitive, small molecule or large molecule. The Seeker is specifically looking for well-supported examples of receptor/ligand inhibition where both methods of inhibition exist. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on February 25, 2015. Late submissions will not be considered.

這是高速度的藥物API的片劑壓制的一個主要問題。活性藥物成分在壓沖過程中的沖頭被粘住而使片劑重量和劑量有所損失產生不同。我們尋找一種計算片劑壓片機高速沖頭上劑量和重量損失的模型，用以改進片劑工藝。具體請看下面英文描述：https://www.innocentive.com/ar/challenge/9933670 AWARD: $10,000 USD | DEADLINE: 2/22/15 | ACTIVE SOLVERS: 9 | POSTED: 1/23/15 Solid dosage forms (e.g. tablets) are the preferred dosage unit for pharmaceutical products. These units are produced by compressing particulate formulations. A major problem in the high speed pressing of tablet formulations of pharmaceutical API’s (Active Pharmaceutical Ingredient) is they sometimes tend to stick to the punches during the compression process. This causes weight loss defects in the tablets and thus costly manufacturing defects during production. A model is required to predict sticking of formulations in high speed presses to prevent losses in production. This is an Ideation Challenge with a guaranteed award for at least one submitted solution. Source: InnoCentive Challenge ID: 9933670 Challenge Overview Tablets are the main dosage form of choice for medicines. They have manufactured by compressing formulations which may consist of blended powders or granules. A major problem in the high speed pressing of tablet formulations of new medicines is they sometimes tend to stick to the surfaces of compaction equipment. This causes tablet weight and hence dose reduction and thus costly manufacturing defects during production. The phenomenon is frequently only observed on scale up due to the lengthy run times at large scale and is difficult to reproduce at smaller scales. New models (or partial model concepts) are required to improve the overall modeling of “stickiness” in tablet compression and predict the extent beforehand. Suggestions for improvements to either process route or equipment or to formulation ingredients to prevent sticking from the models are also desired. This is an Ideation Challenge, which has the following unique features: There is a guaranteed award. The awards will be paid to the best submission(s) as solely determined by the Seeker. The total payout will be $10,000, with at least one award being no smaller than $5,000 and no award being smaller than $2,000. The Solvers are not required to transfer exclusive intellectual property rights to the Seeker. Rather, by submitting a proposal, the Solvers grants to the Seeker a royalty-free, perpetual, and non-exclusive license to use any information included in this proposal.

藥物代謝酶的過程中，肝臟是主要負責將藥物基質脂溶性化合物轉化為水溶性代謝物，可以很容易地通過腎臟排泄的。偶爾，這些代謝產物也會不恰當地和血蛋白結合，從而導致藥物的不良反應。阿斯利康希望尋找一種定量測定共價結合細胞蛋白質的新方法。具體的鏈接請看下面： https://www.innocentive.com/ar/challenge/9933662 AWARD: $25,000 USD | DEADLINE: 3/16/15 | ACTIVE SOLVERS: 74 | POSTED: 1/16/15 Drug metabolism is the enzymatic process by which the body modifies pharmaceutical substrates. The liver is primarily responsible for reactions which convert lipid-soluble compounds into water-soluble metabolites that can easily be excreted by the kidney. Occasionally, these metabolites exhibit chemically reactivity towards host proteins, leading to inappropriate binding that may result in adverse drug reactions. AstraZeneca desires an innovative approach for the quantitative measurement of covalent binding to cellular proteins. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933662 Challenge Overview When new medicines are introduced to the market, not only does the drug need to have a proven therapeutic benefit, but it also must possess an acceptable safety profile. To this end, drug development focuses on minimizing adverse drug reactions (ADRs) and idiosyncratic drug toxicities. ADRs are a major complication of drug therapy and come as a result of drug accumulation and/or the formation of chemically reactive metabolites (CRMs). Formation of CRMs within a cell poses an undesirable chemical liability and for this reason, AstraZeneca desires an innovative approach for the quantitative measurement of covalent binding of metabolites to cellular proteins. ABOUT THE SEEKER AstraZeneca is a global, research-based, biopharmaceutical company with a focus on five key therapeutic areas: 1) cardiovascular & metabolic diseases, 2) oncology, 3) respiratory, inflammation & autoimmunity, 4) neuroscience, and 5) infection. As an innovation-driven, research organization, AstraZeneca recognizes that great ideas come from many sources. Open innovation is an avenue by which ideas can be shared and AstraZeneca recently launched a pavilion to further its commitment to facilitate the advancement of pharmaceutical research.

尋找一種載體某些細胞或分子如蛋白質，DNA，RNA，和microRNA，用這些載體來制備高選擇性的靶向藥物，給藥的方法是讓藥物化合物給藥和輸送到身體的病灶而達到治療效果。具體的要求請看下面鏈接：https://www.innocentive.com/ar/challenge/9933675 AWARD: $30,000 USD | DEADLINE: 2/17/15 | ACTIVE SOLVERS: 108 | POSTED: 1/16/15 Exosomes are membrane-bound vesicles that are produced by many, if not all cell types. Exosomes are able to selectively target certain cells and deliver molecules such as proteins, DNA, RNA, and microRNA. These vesicles are thought to have great potential for targeted drug delivery. The Seeker desires innovative methods for exosome drug loading without significant disruption of the membrane components and properties of the exosome. This Challenge requires only a written proposal. Source: InnoCentive Challenge ID: 9933675 Challenge Overview Drug delivery is the method by which pharmaceutical compounds are administered and transported in the body to achieve therapeutic efficacy. Recently, exosomes have been identified as a novel method to deliver drugs in a targeted manner and their potential is derived from natural components such as specific proteins/lipids contained in the membrane of exosomes. Successful delivery of substantial amounts of therapeutic drugs using exosomes is critically dependent on a highly efficient and broadly applicable methodology for loading exosomes with the therapeutic agent, however at present no such technology is available. The Seeker is looking for one or more technologies that will facilitate exosome drug loading without significant disruption of the membrane components and properties of the exosome.

目前，科學家們只能很有限的預測藥物不同配方的生物利用度。盡管有廣闊的臨床前數據的藥物，我們利用已知的分子性質和制劑在體內的數據并不能完全預測到藥物的溶解性能，使得藥品在體內部分的變化引起整個研究項目的變化。需求者對兩種配方的10個不同的藥物分子已經收集了大量在體外和體內的數據，現在尋求一種模型，能夠使用體外數據和僅有的的物化性質預測不同制劑在體內的性能。具體如下：（https://www.innocentive.com/ar/challenge/9933559） The Seeker is looking for ideas on how to use a variety of properties of molecules, and simple laboratory tests on different formulations to predict the change in a drug’s pharmacokinetic performance in biological systems resulting from different formulations. This is an Ideation Challenge with a guaranteed award for at least one submitted solution. Source: InnoCentive Challenge ID: 9933559 Challenge Overview Currently, scientists possess a limited ability to predict the bioavailability of different formulations of drugs despite vast pre-clinical data for the drugs. Utilizing measured properties of molecules and the dissolution performance of formulations to predict in vivo data is complex, and made more so by the inherent variability of in vivo data due partly to the variability of the test subjects. The Seeker has collected a significant amount of in vitro and in vivo data for two formulations each of 10 different molecules and would like Solvers to present ideas on how to use the in vitro data and simple molecular descriptors to predict the in vivo performance of different formulations. This is an Ideation Challenge, which has the following unique features: There is a guaranteed award. The awards will be paid to the best submission(s) as solely determined by the Seeker. The total payout will be $15,000, with at least one award being no smaller than $5,000 and no award being smaller than $1,000. Submission forwarding occurs during the Challenge. Since submissions will be forwarded to the Seeker throughout the Challenge, please make sure you upload only a finished proposal. You can submit an updated version of your proposal only as a new submission. If you submit an updated version of your proposal, please clearly indicate the new items and/or edits compared to your previous submission. This will allow the Seeker to quickly find the new information and determine how it improves your submission. The Solvers are not required to transfer exclusive intellectual property rights to the Seeker. Rather, by submitting a proposal, the Solvers grants to the Seeker a royalty-free, perpetual, and non-exclusive license to use any information included in this proposal.

我們對治療克羅恩病和潰瘍性結腸炎的新的機理和作用點感興趣，這些可能包括，但不限于，接近病灶或調節菌群，代謝，遺傳，后天產生的抗體。新治療方法可能包括，但不限于，疫苗，基因治療，和小分子化合物，而免疫抑制除外。理想的途徑是先找到IBD發病新機理，再轉化為一種治療新的方法。具體如下：（https://www.innocentive.com/ar/challenge/9933446） Novel Treatment Approaches to Cure Inflammatory Bowel Diseases TAGS: Nature, Chemistry, Life Sciences, Ideation AWARD: $10,000 USD | DEADLINE: 2/16/15 | ACTIVE SOLVERS: 21 | POSTED: 12/16/14 The Seeker for this Challenge desires proposals describing potential approaches for curing Crohn’s disease and ulcerative colitis. The Seeker is interested in novel mechanisms of action that specifically address the pathogenesis of inflammatory bowel diseases (IBD). These may include, but are not limited to, approaches targeting or modulating the microbiota, metabolism, genetic, and epigenetic targets. Platforms may involve, but are not limited to, vaccines, gene therapy, and small molecule compounds. The Seeker is not interested in immunosuppression. Desirable approaches are specifically relevant to the pathogenesis of IBD and can be translated into a cure. This is an Ideation Challenge with a guaranteed award for at least one submitted solution. In addition to the Challenge award, the Seeker is open to establishing potential collaborations with the winning Solver(s) to further investigate proposed mechanisms with the eventual goal of developing a cure for IBD. Source: InnoCentive Challenge ID: 9933446 Challenge Overview The Seeker for this Challenge desires proposals for novel approaches that specifically address the causes of inflammatory bowel diseases (IBD) to enable the development of a cure. The Seeker is interested in unique ideas and new approaches (including gene delivery techniques), but is not interested in approaches that are simply common targets for various immunological conditions. That is, the approach must be specifically relevant to the pathogenesis of IBD and can be translated into a cure. This is an Ideation Challenge, which has the following unique features: There is a guaranteed award. The awards will be paid to the best submission(s) as solely determined by the Seeker. The total payout will be $10,000, with at least one award being no smaller than $5,000 and no award being smaller than $2,000. The Solvers are not required to transfer exclusive intellectual property rights to the Seeker. Rather, by submitting a proposal, the Solvers grants to the Seeker a royalty-free, perpetual, and non-exclusive license to use any information included in this proposal. In addition to the Challenge award, the Seeker is looking to identify potential collaboration partner(s) and are willing to explore research funding agreements.

勃林格殷格翰公司對診斷和治療慢性阻塞性肺疾病以及重癥哮喘患者新方法非常感興趣。針對慢性阻塞性肺病患者或重癥哮喘所造成的呼吸道障礙，他們積極尋求恢復方法并尋找分子靶點開發治療藥物。具體如下：（https://www.innocentive.com/ar/challenge/9933560） Boehringer Ingelheim (the Seeker) is interested in identifying new therapeutic concepts for the treatment of patients with chronic obstructive pulmonary disease (COPD) or severe asthma. The Seeker is specifically searching for molecular targets to develop therapeutic agents for the restoration of the airway epithelial barrier function in patients with COPD or severe asthma. The Seeker is also interested in molecular targets driving the regeneration of the airway epithelium. Submitted solutions that meet the Solution Requirements according to this InnoCentive Challenge Statement will be considered for up to three awards of $15,000 each. However, the Seeker may (i) not award any solution if none of the submitted proposals meets all Solution Requirements or (ii) award only the solution of the highest overall quality with $15,000. The consideration for an award requires the willingness and ability of the Solver to provide the Seeker with a non-exclusive license regarding all intellectual property related to the Challenge according to the terms of the InnoCentive Theroretical (Non-Exclusive-License) Challenge-Specific Agreement. 2. Additional application for Research Funding In addition to consideration for the award(s) Solvers with appropriate qualifications and expertise having access to a suitable research laboratory and equipment can apply for research funding (“Research Funding”) to execute a research plan that is proposed in the submitted solution. The requested funding should not exceed a funding period of 2 years and a total budget of $200,000. The selection of candidates for Research Funding will be conducted after completion of the Challenge, and will require the submission of additional information. The decision to fund research will be at the sole discretion of the Seeker. The Challenge according to No. 1 requires only a written proposal. Qualified Solvers can, in addition, apply for Research Funding according to No. 2. Solvers may be awarded for the (i) submitted solution and may be (ii) selected for Research Funding independently of being awarded. In particular, selection of a solution for the award does not automatically lead to a selection for Research Funding.